Hepatitis Drugs Global Market Report 2024

Hepatitis drugs refer to medications that aggravate liver inflammation. A number of viruses (viral hepatitis), substances, medications, alcohol, certain genetic abnormalities, an overactive immune system that mistakenly assaults the liver (autoimmune hepatitis), and other factors can result in liver inflammation.

The main type of hepatitis drugs interferon alphas, HIV NRTIS, nucleotide polymerase / NS5A inhibitor combinations, hepatitis C protease / NS5A inhibitor combinations, NS5A inhibitors, nucleotide polymerase inhibitors, nucleoside analog antivirals, and thrombopoiesis stimulating agents. The interferon alphas are the innate immune system in response to environmental exposures such as viral infections. Interferon alpha has been developed in different formulations for the treatment but mainly for chronic hepatitis C. The drugs are consumed through oral or injection route of administration and are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies. These drugs are used to treat hepatitis A, hepatitis B, hepatitis C, hepatitis D and hepatitis E.

The hepatitis drugs market research report is one of a series of new reports that provides hepatitis drugs market statistics, including hepatitis drugs industry global market size, regional shares, competitors with a hepatitis drugs market share, detailed hepatitis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis drugs industry. This hepatitis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis drugs market size has grown steadily in recent years. It will grow from $19.34 billion in 2023 to $20.28 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to discovery of antiviral drugs targeting hepatitis viruses, advances in diagnostic technologies for hepatitis, growing awareness of the global burden of hepatitis, expansion of hepatitis vaccination programs, development of interferon-based therapies for hepatitis.

The hepatitis drugs market size is expected to see steady growth in the next few years. It will grow to $23.92 billion in 2028 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to introduction of novel direct-acting antiviral drugs, increasing prevalence of hepatitis infections, rise in government initiatives for hepatitis prevention and treatment, advances in personalized medicine approaches for hepatitis, expansion of access to hepatitis drugs in developing countries. Major trends in the forecast period include transition from interferon-based to interferon-free therapies, development of pan-genotypic antiviral drugs for hepatitis c, integration of non-invasive diagnostic methods for liver fibrosis assessment, exploration of combination therapies for hepatitis b, growing focus on the elimination of viral hepatitis as a public health threat.

The increase in number of cases of different types of hepatitis is significantly driving the growth of the hepatitis drug market. Various types of hepatitis need different drugs for treatment, which increases the demand for hepatitis drugs. For instance, in June 2022, according to the World Health Organization (WHO), a Switzerland based international public health organization, 296 million people had a chronic hepatitis B infection, with an average of 1.5 million new infections every year. This increasing number of hepatitis infections will invariably increase the need for and consumption of hepatitis drugs. Thus, the increasing number of different types of hepatitis is expected to propel the growth of hepatitis drugs in the forecast period.

The rising investment in research and development is expected to propel the growth of the hepatitis drug market in the coming years. Research and development refer to the research operations carried out by businesses, institutions, or organizations to discover, experiment, invent, and develop new goods, processes, or services, or to enhance current ones. Investments in research and development contribute considerably to financial growth, societal improvement, corporate success, and sustainability, promoting advancement and creativity in several areas. For instance, in May 2023, according to the Parliament of Australia, an Australia-based government supreme legislative branch, the government is going to invest $12.1 billion in research and development in 2022-23. This is a 3.2% increase over the previous year. Therefore, the rising investment in research and development is driving the hepatitis drugs market.

New product launches are a significant trend in the hepatitis drugs market. The key players in the hepatitis drugs sector are focusing on launching new products for hepatitis treatments to strengthen their position in the market. For instance, in June 2021, the Malaysian National Pharmaceutical Regulatory Agency (NPRA) issued conditional authorization for a secure and efficient hepatitis C treatment created by the Malaysian Ministry of Health, the non-profit research and development organization Drugs for Neglected Diseases Initiative (DNDi), the Egyptian pharmaceutical company Pharco, the Malaysian pharmaceutical company Pharmaniaga Berhad, and the non-profit organization Médecins Sans Frontières/Doctors Without Borders (MSF). This is the first HCV medication created through South-South collaboration, as well as with non-profit finance and clinical assistance.

Major companies operating in the hepatitis drug market are focusing on innovative products, such as Vemlidy (tenofovir alafenamide), to better meet the needs of their existing consumers. Vemlidy (Tenofovir alafenamide) is an antiretroviral medicine belonging to the nucleotide reverse transcriptase inhibitor (NRTI) class used to treat HIV (Human Immunodeficiency Virus) and persistent hepatitis B virus infections. For instance, in November 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, announced the approval of Vemlidy (tenofovir alafenamide) at a dose of 25 mg for the treatment of chronic hepatitis B virus infection in pediatric individuals. Vemlidy is a new, targeted tenofovir prodrug used as a once-daily therapy for individuals with persistent HBV infection with compensatory liver disease. It is indicated as a recommended or first-line therapy for individuals with chronic HBV and aggravated liver disease in AASLD and EASL recommendations.

In March 2021, Gilead Sciences, a US-based biopharmaceutical company acquired MYR GmbH for cash consideration of $1.55 billion (€1.45 billion). As a result of the acquisition, Gilead leverages the MYR GmbH’s new drugs and expansion of the market globally in providing better treatment for hepatitis. MYR GmbH is a Germany-based company that develops inhibitors for chronic hepatitis B and D infections.

Major companies operating in the in the hepatitis drugs market report are Gilead Sciences Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Abbott Laboratories, AbbVie Inc., Arbutus Biopharma Corporation, Aspen Pharmacare Holdings Limited, Aurobindo Pharma Limited, Beijing Kawin Technology Share-Holding Co. Ltd., Beximco Pharmaceuticals Ltd., Biocon Limited, Bristol-Myers Squibb Company, Cadila Healthcare Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Enanta Pharmaceuticals Inc., Hetero Drugs Limited, Laurus Labs Limited, Lupin Pharmaceuticals Inc., Micro Labs Limited, Mylan N. V., Natco Pharma Limited, Novartis International AG, Roche Holding AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited, Vir Biotechnology Inc., Agenus Inc., Genentech Inc., Eisai Pharmaceuticals India Pvt. Ltd.

North America was the largest region in the hepatitis drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hepatitis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The hepatitis drugs market consists of sales of ribavirin, elbasvir-grazoprevir, and glecaprevir-pibrentasvir. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.